At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,800 enrolled
Drug / intervention
Tyrosine kinase inhibitorsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs Using the LabRx Database
In Brief
An observational study evaluating Tyrosine kinase inhibitors for Cancer. Completed, enrolled 3,800 participants.
Detailed Summary
A retrospective cohort study using the LabRx medical claims database will be performed to address these objectives. The primary objective of this project is to examine the background rates of liver function test (LFT) abnormalities in cancer patients treated with tyrosine kinase inhibitors (TKIs).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedApr 2010
Primary CompletionOct 2010
TodayJul 2026
First PostedApr 2, 2010
Enrollment StartFeb 1, 2009
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.3 years ago
Interventions
Tyrosine kinase inhibitorsdrug
Lapatinib, erlotinib, gefitinib, dasatinib, imatinib, nilotinib (analyzed as a class of drugs, not by individual drug)